ML-792
Based on 36 publication(s) in Google Scholar
ML-792 is a potent and selective inhibitor of SAE/SUMO1 and SAE/SUMO2 in enzymatic assays (IC50 values of 3 and 11 nM, respectively) compared with NAE/NEDD8 and UAE/ubiquitin (IC50> values of 32 μM and >100 μM, respectively).
For research use only. We do not sell to patients.
- Purity: 99.76%
- CAS No.: 1644342-14-2
- Formula: C21H23BrN6O5S
- Molecular Weight:551.41
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) ML-792
More- Mol Cell. 2024 Sep 5;84(17):3271-3287.e8. [Abstract]
- Mol Cell. 2023 Feb 16;83(4):539-555.e7. [Abstract]
- Mol Cell. 2020 Jul 2;79(1):54-67.e7. [Abstract]
- Nat Commun. 2025 Aug 29;16(1):8074. [Abstract]
- Nat Commun. 2025 Aug 6;16(1):7248. [Abstract]
- Nat Commun. 2022 Nov 11;13(1):6840. [Abstract]
- Nat Commun. 2022 Sep 29;13(1):5726. [Abstract]
- Nat Commun. 2022 Sep 3;13(1):5204. [Abstract]
- Cell Death Differ. 2025 Jun;32(6):1041-1057. [Abstract]
- Adv Sci (Weinh). 2025 Jun 10:e05963. [Abstract]
- Sci Adv. 2024 Nov 15;10(46):eadp6567. [Abstract]
- Sci Adv. 2023 Dec 8;9(49):eadi6681. [Abstract]
- Sci Adv. 2023 Dec 8;9(49):eadl2108. [Abstract]
- Cell Mol Biol Lett. 2024 Jan 16;29(1):15. [Abstract]
- Cell Genom. 2024 Jan 10;4(1):100471. [Abstract]
- EMBO Mol Med. 2023 Sep 11;15(9):e16431. [Abstract]
- Mol Syst Biol. 2024 May 14. [Abstract]
- Cell Chem Biol. 2021 Oct 21;28(10):1394-1406.e10. [Abstract]
- Cell Death Discov. 2023 Jul 15;9(1):248. [Abstract]
- Cell Rep. 2024 Mar 18;43(3):113924. [Abstract]
- Cell Rep. 2022 Mar 22;38(12):110534. [Abstract]
- Cell Rep. 2021 Dec 7;37(10):110080. [Abstract]
- Hepatol Int. 2025 Jun;19(3):529-546. [Abstract]
- Int J Mol Med. 2025 Sep;56(3):141. [Abstract]
- Cell Oncol (Dordr). 2024 Apr;47(2):513-532. [Abstract]
- Cell Signal. 2025 Nov:135:112036. [Abstract]
- Am J Pathol. 2020 Dec;190(12):2464-2477. [Abstract]
- IUBMB Life. 2025 Aug;77(8):e70047. [Abstract]
- Mol Carcinog. 2023 May;62(5):700-715. [Abstract]
- Mol Biol Cell. 2023 May 1;34(5):br6. [Abstract]
- J Biochem. 2026 Feb 13:mvag011. [Abstract]
- bioRxiv. 2026 Jun 26.
- bioRxiv. 2024 Nov 15:2024.11.15.623791. [Abstract]
- bioRxiv. 2023 Dec 9.
- bioRxiv. 2023 Oct 17.
- Research Square Preprint. 2023 Sep 11.
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
WB
-
RT-PCR
-
WB
Biological Activity
IC50: 3 nM (SAE/SUMO1), 11 nM (SAE/SUMO2)[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | EC50 |
0.09 μM
Compound: ML-792
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo luminescent assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo luminescent assay
|
[PMID: 33631934] |
| OCI-Ly10 | EC50 |
0.055 μM
Compound: ML-792
|
Cytotoxicity against human OCI-LY10 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo luminescent assay
Cytotoxicity against human OCI-LY10 cells assessed as reduction in cell viability after 72 hrs by CellTiter-Glo luminescent assay
|
[PMID: 33631934] |
ML-792 (0.0007-5 μM; 4 hours) inhibits SAE and SUMO-pathway activities in HCT116 cells[1].
ML-792 (0.001-10 μM; 72 hours ) inhibits cell proliferation and decreases cancer cell viability in MDA-MB-468, MDA-MB-231, HCT116, Colo-205, and A375[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human breast cancer cells MDA-MB-468 and MDA-MB-231; human colon carcinoma cells HCT116 and Colo-205; human melanoma cell line A375
-
Concentration:0.001, 0.01, 0.1, 1, 10 μM
-
Incubation Time:72 hours
-
Result:Demonstrated a dose-dependent viability effect with EC50 values of 0.06 μM in MDA-MB-468 cells to 0.45 μM in A375 cells.
-
Cell Line:HCT116 cells
-
Concentration:0, 0.0007, 0.002, 0.007, 0.02, 0.06, 0.19, 0.56, 1.7, 5 μM
-
Incubation Time:4 hours
-
Result:Revealed a dose-dependent decrease in the SAE and UBC9 thioester levels.
Chemical Information
-
CAS No. 1644342-14-2
-
Appearance Solid
-
Molecular Weight 551.41
-
Formula C21H23BrN6O5S
-
Color White to off-white
-
SMILES
O=S(OC[C@@H]1[C@@H](O)C[C@H](NC2=NC=NC=C2C(C3=NN(CC4=CC=CC(Br)=C4)C=C3)=O)C1)(N)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (36)
-
Journal Impact Factor
-
Most Recent
-
Mol Cell
Histone chaperone HIRA, promyelocytic leukemia protein, and p62/SQSTM1 coordinate to regulate inflammation during cell senescence. [Abstract]2024 Sep 5;84(17):3271-3287.e8. PMID: 39178863
ML-792 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2024 Sep 5;84(17):3271-3287.e8. [Abstract]
Real-time qPCR analysis of SASP genes in the presence of ML-792 (0,1,10 nM).
-
Mol Cell
SUMOylation of HNRNPA2B1 modulates RPA dynamics during unperturbed replication and genotoxic stress responses. [Abstract]2023 Feb 16;83(4):539-555.e7. PMID: 36702126
ML-792 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2023 Feb 16;83(4):539-555.e7. [Abstract]
HEK293T cells transfected with FLAG-HNRNPA2 were treated with various concentrations of ML-792 (0, 2, 5 μM) for 16 h. HNRNPA2SUMO and SUMO1 conjugates were detected using anti-FLAG and anti-SUMO1 antibodies, respectively.
-
Mol Cell
The Nuclear SUMO-Targeted Ubiquitin Quality Control Network Regulates the Dynamics of Cytoplasmic Stress Granules. [Abstract]2020 Jul 2;79(1):54-67.e7. PMID: 32521226
ML-792 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2020 Jul 2;79(1):54-67.e7. [Abstract]
Treatment of cells with the SUMO inhibitor ML-792 for 4 or 24 h causes a dramatic recruitment of FUSP525L in G3BP1-positive SGs. By contrast, wild-type FUS does not accumulate in these structures upon inhibition of SUMOylation.
-
Nat Commun
NEXN protects against vascular calcification by promoting SERCA2 SUMOylation and stabilization. [Abstract]2025 Aug 29;16(1):8074. PMID: 40883305
ML-792 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 29;16(1):8074. [Abstract]
Western blot of the protein expression of SERCA2 SUMOylation in human VSMCs infected with Ad-NEXN, treated with ML792 (10 μM), and then cultured for 7 days in GM.
-
Nat Commun
IRX3 controls a SUMOylation-dependent differentiation switch in adipocyte precursor cells. [Abstract]2025 Aug 6;16(1):7248. PMID: 40769964
ML-792 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 6;16(1):7248. [Abstract]
Cells were treated with ML-792 (0.5 µM) from days −2 to 9 of adipocyte differentiation, fluorescence and brightfield microscopy images of cells stained with Bodipy lipid dye on day 9.
ML-792 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Aug 6;16(1):7248. [Abstract]
Cells treated with either vehicle or 0.5 µM ML-792 throughout the differentiation with alkaline phosphatase staining.
-
Nat Commun
pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation. [Abstract]2022 Nov 11;13(1):6840. PMID: 36369429 -
Nat Commun
Exploration of nuclear body-enhanced sumoylation reveals that PML represses 2-cell features of embryonic stem cells. [Abstract]2022 Sep 29;13(1):5726. PMID: 36175410 -
Nat Commun
Suppression of ACE2 SUMOylation protects against SARS-CoV-2 infection through TOLLIP-mediated selective autophagy. [Abstract]2022 Sep 3;13(1):5204. PMID: 36057605 -
Cell Death Differ
Redox regulation of TRIM28 facilitates neuronal ferroptosis by promoting SUMOylation and inhibiting OPTN-selective autophagic degradation of ACSL4. [Abstract]2025 Jun;32(6):1041-1057. PMID: 39875520 -
Adv Sci (Weinh)
Tumor Small Extracellular Vesicle-Transmitted LncRNA CATED Promotes Platinum-Resistance in High-Grade Serous Ovarian Cancer. [Abstract]2025 Jun 10:e05963. PMID: 40492382 -
Sci Adv
2024 Nov 15;10(46):eadp6567. PMID: 39536107 -
Sci Adv
RAD54L2-mediated DNA damage avoidance pathway specifically preserves genome integrity in response to topoisomerase 2 poisons. [Abstract]2023 Dec 8;9(49):eadi6681. PMID: 38055811 -
Sci Adv
2023 Dec 8;9(49):eadl2108. PMID: 38055822 -
Cell Mol Biol Lett
SUMOylation modulates eIF5A activities in both yeast and pancreatic ductal adenocarcinoma cells. [Abstract]2024 Jan 16;29(1):15. PMID: 38229033 -
Cell Genom
Multi-omics integration identifies cell-state-specific repression by PBRM1-PIAS1 cooperation. [Abstract]2024 Jan 10;4(1):100471. PMID: 38190100 -
EMBO Mol Med
Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response. [Abstract]2023 Sep 11;15(9):e16431. PMID: 37485814 -
Mol Syst Biol
A continuum of zinc finger transcription factor retention on native chromatin underlies dynamic genome organization. [Abstract]2024 May 14. PMID: 38745107 -
Cell Chem Biol
Targeting SUMOylation dependency in human cancer stem cells through a unique SAE2 motif revealed by chemical genomics. [Abstract]2021 Oct 21;28(10):1394-1406.e10. PMID: 33979648 -
Cell Death Discov
Loss of PML nuclear bodies in familial amyotrophic lateral sclerosis-frontotemporal dementia. [Abstract]2023 Jul 15;9(1):248. PMID: 37454169 -
Cell Rep
2024 Mar 18;43(3):113924. PMID: 38507413 -
Cell Rep
2022 Mar 22;38(12):110534. PMID: 35320709 -
Cell Rep
The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability. [Abstract]2021 Dec 7;37(10):110080. PMID: 34879279 -
Hepatol Int
TRIM28 functions as SUMO ligase to SUMOylate TRAF6 and regulate NF-κB activation in HBV-replicating cells. [Abstract]2025 Jun;19(3):529-546. PMID: 39920527 -
Int J Mol Med
SENP1 promotes p27kip1 nuclear export though enhanced SUMOylation in cholangiocarcinoma leading to increased cell proliferation and chemoresistance. [Abstract]2025 Sep;56(3):141. PMID: 40682835 -
Cell Oncol (Dordr)
SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma. [Abstract]2024 Apr;47(2):513-532. PMID: 38055116 -
Cell Signal
Chemerin-stimulated HSP90AB1 SUMOylation promotes monocyte activation and ERK1/2 phosphorylation via β2 integrin. [Abstract]2025 Nov:135:112036. PMID: 40744335 -
Am J Pathol
Heat Shock Protein 27 Enhances SUMOylation of Heat Shock Protein B8 to Accelerate the Progression of Breast Cancer. [Abstract]2020 Dec;190(12):2464-2477. PMID: 33222991 -
IUBMB Life
RING Finger Protein 4 (RNF4) Reduces Nonalcoholic Fatty Liver Disease Accumulation by Promoting the SUMOylation of HIF-2α and Regulating the PPARα Signaling Pathway. [Abstract]2025 Aug;77(8):e70047. PMID: 40739771 -
Mol Carcinog
Knockdown of UBE2I inhibits tumorigenesis and enhances chemosensitivity of cholangiocarcinoma via modulating p27kip1 nuclear export. [Abstract]2023 May;62(5):700-715. PMID: 36825757 -
Mol Biol Cell
2023 May 1;34(5):br6. PMID: 36989032 -
J Biochem
2026 Feb 13:mvag011. PMID: 41679964 -
-
bioRxiv
Identification of Novel Modulators of the ALT Pathway Through a Native FISH-Based Optical Screen. [Abstract]2024 Nov 15:2024.11.15.623791. PMID: 39605432 -
-
-
Solvent & Solubility
DMSO : 100 mg/mL (181.35 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (3.77 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8135 mL | 9.0677 mL | 18.1353 mL | 45.3383 mL |
| 5 mM | 0.3627 mL | 1.8135 mL | 3.6271 mL | 9.0677 mL | |
| 10 mM | 0.1814 mL | 0.9068 mL | 1.8135 mL | 4.5338 mL | |
| 15 mM | 0.1209 mL | 0.6045 mL | 1.2090 mL | 3.0226 mL | |
| 20 mM | 0.0907 mL | 0.4534 mL | 0.9068 mL | 2.2669 mL | |
| 25 mM | 0.0725 mL | 0.3627 mL | 0.7254 mL | 1.8135 mL | |
| 30 mM | 0.0605 mL | 0.3023 mL | 0.6045 mL | 1.5113 mL | |
| 40 mM | 0.0453 mL | 0.2267 mL | 0.4534 mL | 1.1335 mL | |
| 50 mM | 0.0363 mL | 0.1814 mL | 0.3627 mL | 0.9068 mL | |
| 60 mM | 0.0302 mL | 0.1511 mL | 0.3023 mL | 0.7556 mL | |
| 80 mM | 0.0227 mL | 0.1133 mL | 0.2267 mL | 0.5667 mL | |
| 100 mM | 0.0181 mL | 0.0907 mL | 0.1814 mL | 0.4534 mL |